Table 1: Summary of baseline characteristics by 90-day outcome.

Alive ( )Dead ( )Lost to follow-up ( ) value

Female sex: (%)151 (57%) 19 (46%) 30 (67%) 0.16
Age: years (IQR)34 (29: 38) 35 (30: 40.2) 30 (26: 33) <0.01
Body mass index: kg/m218.8 (17: 21) 16.7 (15.9: 18.6) 17 (15.8: 20.3) <0.01
lymphocyte count: cells/µL109 (57: 158) 50 (27: 129) 36 (22: 85) <0.01
Phosphate (mmol/L) 1.3 (1.1: 1.4) 1.1 (0.9: 1.3) 1.3 (1.2: 1.5) <0.01
Albumin (g/L) 31 (26: 35) 24 (20: 30) 32 (24: 35) <0.01
Ferritin (mg/L) 207 (77: 506) 601 (313: 943) 209 (123: 487) <0.01
C-reactive protein (mg/L) 5.5 (1.4: 21) 15.1 (6.7: 30) 4.6 (1.8: 20) 0.04
Receiving concomitant tuberculosis treatment (%)61 (23%)9 (22%)10 (22%)0.99
ART regimen: (%)*
 AZT-3TC-EFV 9 (3%) 1 (3%) 1 (3%)
 AZT-3TC-NVP 96 (37%) 13 (33%) 6 (15%)
 D4T-3TC-EFV 13 (5%) 4 (10%) 1 (3%)
 D4T-3TC-NVP 94 (36%) 18 (46%) 13 (33%)
 TDF-FTC-EFV 3 (1%) 0 3 (8%)
 TDF-FTC-NVP 48 (18%) 3 (8%) 16 (40%)
TDF-containing regimen: (%)0.120
 TDF-based51 (19%)3 (8%)19 (47%)
 Not TDF-based212 (81%)36 (92%)21 (53%)

Continuous variables are reported as medians (interquartile range). The distribution of study characteristics for participants by 90-day outcome is compared using the chi-square test: and continuous variables using the Wilcoxon rank-sum test.
*Ten participants were missing data on first ART regimen.
Abbreviations: ART: antiretroviral therapy; IQR: interquartile range; 3TC: lamivudine; d4T: stavudine; EFV: efavirenz; FTC: emtricitabine; NVP: nevirapine; TDF; tenofovir; ZDV: zidovudine.